These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23479468)
21. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Sormani MP; Bruzzi P; Comi G; Filippi M Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228 [TBL] [Abstract][Full Text] [Related]
22. [A place of first-line drugs in treatment of multiple sclerosis]. Kasatkin DS Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741 [TBL] [Abstract][Full Text] [Related]
24. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Ziemssen T; Neuhaus O; Hohlfeld R Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654 [TBL] [Abstract][Full Text] [Related]
25. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS; Narayana PA; Johnson KP; Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192 [TBL] [Abstract][Full Text] [Related]
26. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neuhaus O; Farina C; Wekerle H; Hohlfeld R Neurology; 2001 Mar; 56(6):702-8. PubMed ID: 11288751 [No Abstract] [Full Text] [Related]
28. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone). Losy J; Michałowska-Wender G; Kurdyńska A; Wender M Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210 [TBL] [Abstract][Full Text] [Related]
30. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Lu E; Dahlgren L; Sadovnick A; Sayao A; Synnes A; Tremlett H Mult Scler; 2012 Apr; 18(4):460-7. PubMed ID: 21914689 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963 [TBL] [Abstract][Full Text] [Related]
32. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092 [TBL] [Abstract][Full Text] [Related]
33. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate]. Federal service on surveillance in healthcare and social development (Roszdravnadzor) Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162 [TBL] [Abstract][Full Text] [Related]
34. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Hussien Y; Sanna A; Söderström M; Link H; Huang YM Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948 [TBL] [Abstract][Full Text] [Related]
35. [Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review]. Shmidt TE Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):123-8. PubMed ID: 23378992 [TBL] [Abstract][Full Text] [Related]
36. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M; Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077 [TBL] [Abstract][Full Text] [Related]
37. [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis]. Petrova LV; Boĭko AN; Batysheva TT; Gusev EI Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):41-5. PubMed ID: 21311486 [TBL] [Abstract][Full Text] [Related]
38. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Clegg A; Bryant J; Milne R Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743 [No Abstract] [Full Text] [Related]